Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors

Expert Opinion on Biological Therapy

Volumn 8, Issue 8, 2008, Pages 1167-1176

  Camidge, D Ross ^a,b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Apomab; Death receptor 5 TRAIL receptor 2; Monoclonal antibody; Solid tumots

Indexed keywords

AMG 655; ANTINEOPLASTIC AGENT; APOMAB; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DEATH RECEPTOR 5; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LEXATUMUMAB; MAPATUMUMAB; MONOCLONAL ANTIBODY; PACLITAXEL; PEMETREXED; RECOMBINANT APOLIPOPROTEIN 2L; RECOMBINANT PROTEIN; RITUXIMAB;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE SEVERITY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MEDLINE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVARY CANCER; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 47949092316     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.8.1167     Document Type: Review

References (43)

1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta:American Cancer Society; 2008. Available from:www.cancer.org
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
3. Camidge DR. The potential of DR4- and DR5-directed therapies in lung cancer. Clin Lung Cancer 2007;8:413-9
4. Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in anti-cancer therapeutics [manuscript submitted]. Lancet Oncol 2008
5. Ashkenazi A. Targeting death and decoy receptors in the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2(6):420-30
6. Hill MM, Adrain C, Martin SJ. Portrait of a killer:the mitochondrial apoptosome emerges from the shadows. Mol Interv 2003;3(1):19-26
7. Peter ME, Krammer PH. The CD95(APO-l/Fas) DISC and beyond. Cell Death Differ 2003;10:26-35
8. Adams JM, Cory S. The bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37
9. Humphreys RC. Development and evaluation of cancer therapeutic agents targeting TRAIL receptor 1 and 2. In:LaRochelle WJ and Shimkets RA, editors, Cancer drug discovery and development:the oncogenomics handbook. Humana Press, Inc.; Totawa, NJ; 2005. p. 659-76
10. Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611-20
11. Huang Y, Sheikh MS. TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol 2007;224:284-9
12. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signaling:Decisions between life and death. Int J Biochem Cell Biol 2007;39:1462-75
13. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104(2):155-62
14. Adams C, Totpal K, Lawrence D, et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008;15:751-61
15. Daniel DL, Yang B, Totpal K, et al. Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non-Hdgkin's lymphoma [abstract B32]. AACR-NCI-EORTC Proceedings; 2007
16. Camidge DR, Herbst RS, Gordon M, et al. A phase I safety and pharmacokinetic study of Apomab, a human DR5 agonist antibody in patients with advanced cancer [abstract 3582]. ASCO Proceedings; 2007
17. Tolcher AW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biological correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis inducing-ligand receptor-1. J Clin Oncol 2007;25(11):1390-5
18. Hotte S, Oza AM, Le LH, et al. Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma [abstract 208]. EORTC-NCI-AACR Proceedings; 2004
19. Younes A, Vose J, Zelenetz A, et al. Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL) [abstract 489]. ASH Proceedings; 2005
20. Greco FA, Bonomi P, Crawford J, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008; published online 5 February 2008, doi:10.1016/j.lungcan.2007.12.011
21. Kanzler S, Trarbach T, Heinemann V, et al. Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed or refractory colorectal cancer (CRC) [abstract 630]. ECCO 13 - the European Cancer Conference; 2005
22. Chow LQ, Eckhardt SG, Gustafson DL, et al. HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies. Results of a Phase I and PK study [abstract 2525]. ASCO Proceedings; 2006
23. Mom CH, Sleijfer S, Gietema JA, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin:a Phase Ib study in patients with advanced solid malignancies [abstract 202]. AACR-NCI-EORTC International Conference on Molecular Therapeutics; 2006
24. Plummer R, Attard G, Pacey S, et al. Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13(20):6187-6194
25. LoRusso P, Hong D, Heath E, et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors [abstract 3534]. ASCO Proceedings; 2007
26. Sikic BI, Wakelee HA, Mehren MV, et al. A Phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine pemetrexed, doxorubicin, or FOLFIRI. [abstract 14006]. ASCO Proceedings; 2007
27. Herbst RS, Mendolson DS, Ebbinghaus S, et al. A Phase I safety and pharmacokinetic study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer [abstract 3013]. ASCO Proceedings; 2006
28. Ling J, Herbst RS, Mendelson DS, et al. Apo2L/TRAIL pharmacokinetics in a Phase Ia trial in advanced cancer and lymphoma [abstract 3047]. ASCO Proceedings; 2006
29. Pan Y, Xu R, Peach M, et al. Application of pharmacodynamic assays in a Phase Ia trial of Apo2L/TRAIL in patients with advanced tumors [abstract 3535]. ASCO Proceedings; 2007
30. Hylander BL, Pitoniak R, Pentrante RB, et al. The anti-tumor effect of Apo2L/TRAJL on patient pancreatic adenocarciomas grown as xenografts in SCID mice. J Transl Med 2005;3:22-35
31. Koschny R, Walczak H, Ganten TM. The promise of TRAIL - potential and risks of a novel anticancer therapy. J Mol Med 2007;85:923-35
32. Spalding AC, Jotte RM, Scheinman RI, et al. TRAIL and inhibitors of apoptosis are opposing determinants of NF-κB-dependent, genotoxin-induced apoptosis of cancer cells. Oncogene 2002;21:260271
33. Lippa MS, Strockbine LD, Le TT, et al. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells. Apoptosis 2007 [Epub ahead of print]
34. Carlo-Stella C, Lavazza C, Locatelli A, et al. Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res 2007;13(8):2313-7
35. Cheng J, Hylander BL, Baer MR, et al. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther 2006;5:1844-53
36. Bin L, Thorburn J, Thomas LR, et al. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through DR4 receptor by competing for ligand binding. J Biol Chem 2007;282:28189-94
37. Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics:resistance mechanisms and strategies to avoid them. Drug Resist Updat 2008;11:17-24
38. Wagner K, Punnoose E, Januario T et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13(9):1070-7
39. Behbakht K, Qamar L, Aldridge CS, et al. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 2007;67:3036-42
40. Henson ES, Johnston JB, Gibson SB. The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 2008;49:27-35
41. Park S-M, Schickel R, Peter ME. Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr Opin Cell Biol 2005;17:610-6
42. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-5
43. Rowinsky EK. Targeted induction of apoptosis in cancer management:The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005;23(36):9394-407